pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
  1. pharmadog
  2. ›drugs
  3. ›Cancer Program
drug · antibody
save

Cancer Program

Phase 2updated 3mo ago
by Mirror Biologics Inc🔗 ChEMBL
Phase 2
community read0 votes

🐶 often sniffed alongside

top 5
  • tagApproval256 co-mentions · 128 sources
  • drugpembrolizumab256 co-mentions · 128 sources
  • drugKEYTRUDA256 co-mentions · 128 sources
  • drugKEYTRUDA QLEX133 co-mentions · 128 sources
  • drug(berahyaluronidase alfa + pembrolizumab)5 co-mentions · 5 sources

Antibody drug with a maximum clinical stage of Approval (across all indications), with 9 approved and 146 investigational indications.

targets

Programmed cell death protein 1

all catalysts(0)

nothing on the calendar yet

News(10)

  • Cancer vaccine win restores Wall Street’s faith in Moderna
    Moderna gained $45 billion in market value in a single day, a surge that brought the company’s stock to levels not seen since 2024 — and saddled it with expectations that may be tough to meet.
    biopharma_dive · 11h ago
  • Merck’s Moderna-partnered vaccine success clears view of post-Keytruda future
    Investors had been pessimistic about the probability of success for the personalized cancer vaccine intismeran autogene, so the Phase 3 win was a welcome surprise.
    biospace · 15h ago
  • Merck-Moderna cancer vaccine win spurs stock jump, speculation of Keytruda-like impact
    As the dust settles on phase 3 data that added $45 billion to Moderna’s market cap, analysts have begun to ask a question that could define cancer care in the coming years: Can use of the vaccine b…
    fiercebiotech · 17h ago
  • Trump's FDA pick Overton good for psychedelics, new pain meds but bad for vaccines: Analysts
    If confirmed by the Senate, Heidi Overton—officially revealed Wednesday as President Donald Trump’s choice for FDA commissioner—is expected to be a boon for developers of psychedelic therapeutics a…
    biospace · 1d ago
  • Moderna stock nearly doubles as Merck-partnered mRNA cancer vaccine meets Phase 3 goal
    Melanoma was slower to recur in patients receiving Merck and Moderna's mRNA vaccine with Keytruda, supporting use of the combination in adjuvant treatment. The partners plan to take the data to the…
    biospace · 1d ago
  • Moderna and Merck cancer vaccine returns ‘landmark’ result in melanoma
    At an interim data check, investigators of a key trial found the individualized mRNA treatment kept disease from returning and stopped its spread, sparking a surge in Moderna shares.
    biopharma_dive · 1d ago
  • STAT+: Moderna and Merck say mRNA cancer vaccine succeeded in late-stage melanoma trial
    A personalized mRNA cancer vaccine succeeded in a late-stage melanoma study, results that could herald a new, powerful approach in oncology.
    stat · 1d ago
  • Merck, Moderna’s personalized cancer vaccine slows recurrence in phase 3, setting up approval push
    Merck & Co. and Moderna's personalized mRNA cancer vaccine has successfully lengthened recurrence-free survival when paired with Keytruda for patients with high-risk skin cancer. The phase 3 win se…
    fiercebiotech · 2d ago
  • Sandoz inks $322M Henlius deal for rights to as many as 10 biosimilars
    The initial batch of biosimilars includes copies of Amgen, Eli Lilly and GSK drugs that collectively generate billions of dollars in annual revenues.
    biospace · 2d ago
  • Regeneron ends eye disease study due to antibody's safety profile
    The discontinuation of the uveitis study adds to Regeneron’s series of clinical setbacks, including the Phase 3 failures of the Dupixent follow-up itepekimab and an investigational combo regimen fo…
    biospace · 2d ago
view all news mentions →
trade names
Keytruda, Pembrolizumab component of mk 7684a, Pembrolizumab component of mk-1308a
MOA
Programmed cell death protein 1 inhibitor
indication
Metastatic Colorectal Cancer
phase
phase_2
Data sources
ClinicalTrials.gov · OpenTargets
last refreshed 7m ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?